Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.

Cite this paper

@article{Motzer2012RandomizedPI, title={Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma.}, author={Robert John Motzer and Thomas E. Hutson and Mark R Olsen and Gary R. Hudes and John M. Burke and William Jeffrey Edenfield and George Wilding and Neeraj Agarwal and John A Thompson and David F. Cella and Akintunde Bello and Beata Korytowsky and Jinyu Yuan and Olga Valota and Bridget A Martell and Subramanian Hariharan and Robert Alan Figlin}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2012}, volume={30 12}, pages={1371-7} }